- Home
- TARS
as 12-17-2024 4:00pm EST
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 1.8B | IPO Year: | 2020 |
| Target Price: | $54.20 | AVG Volume (30 days): | 469.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.70 | EPS Growth: | N/A |
| 52 Week Low/High: | $18.84 - $54.44 | Next Earning Date: | 11-13-2024 |
| Revenue: | $129,621,000 | Revenue Growth: | 801.96% |
| Revenue Growth (this year): | 895.24% | Revenue Growth (next year): | 73.78% |
Latest Tarsus Pharmaceuticals Inc. News
TARS Breaking Stock News: Dive into TARS Ticker-Specific Updates for Smart Investing
Zacks
14 days ago
Wall Street Analysts Think Tarsus Pharmaceuticals (TARS) Could Surge 26.98%: Read This Before Placing a Bet
Zacks
a month ago
Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's is How to Trade
Simply Wall St.
a month ago
Tarsus Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
MT Newswires
a month ago
Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $65 From $63, Maintains Outperform Rating
GuruFocus.com
a month ago
Tarsus Pharmaceuticals Inc (TARS) Q3 2024 Earnings Call Highlights: Record Sales and Strategic ...
Zacks
a month ago
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates
MT Newswires
a month ago
Tarsus Pharmaceuticals Q3 Loss Narrows, Revenue Surges
GlobeNewswire
a month ago
Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
Compare TARS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TARS Tarsus Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.